Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery:: A randomized, double-blind placebo-controlled trial
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery:: A randomized, double-blind placebo-controlled trial
复制标题
DOI：
10.1038/sj.clpt.6100473
复制
发表时间：
2008-07-01
影响因子：
6.7
通讯作者：
Schwab, M.
中科院分区：
文献类型：
--
作者：
Moerike, K.;Kivistoe, K. T.;Schwab, M.
我们研究了普罗帕酮预防心脏手术后房性快速性心律失常的疗效，以及CYP 2D 6多态性与普罗帕酮的疗效、药代动力学和耐受性之间的可能关系。160例患者随机（双盲）接受普罗帕酮（n = 78）或安慰剂（n = 82）1周后心脏手术。普罗帕酮组的患者在1小时内接受1 mg/ kg输注，随后以4 mg/kg/24 h的速率持续输注至次日早晨，随后口服450 mg/天直至术后第6天。普罗帕酮组有37名患者完成了试验，安慰剂组有45名。心律失常的发生率普罗帕酮组低于安慰剂组（29.7%比53.3%，P < 0.05;相对危险度0.56）。血浆普罗帕酮浓度受CYP 2D 6基因型衍生表型的显著影响。
We studied the efficacy of propafenone in preventing atrial tachyarrhythmias after cardiac surgery, and the possible relationships between CYP2D6 polymorphism and the efficacy, pharmacokinetics, and tolerability of propafenone. One hundred and sixty patients were randomized (double blind) to receive propafenone (n = 78) or placebo (n = 82) for 1 week after cardiac surgery. The patients who were assigned to the propafenone group received 1 mg/ kg infused in 1 h, followed by a continuous infusion at a rate of 4 mg/kg/24 h until the following morning, and subsequently 450 mg/ day orally until the sixth postoperative day. Thirty-seven patients completed the trial in the propafenone group and 45 in the placebo group. The frequency of occurrence of atrial tachyarrhythmia was lower in the propafenone group than in the placebo group (29.7% vs. 53.3%, P < 0.05; relative risk, 0.56). Plasma propafenone concentrations were markedly influenced by CYP2D6 genotype-derived phenotype.